



Building
A Global Success

Facts & Figures

Founded in

1978

in Jordan

Fast growing multinational
pharmaceutical group based in

London, UK

Global presence with more
than

8,800

employees worldwide

2,517 mUSD

Revenue in

2022

3rd

largest portfolio
of generic injectable
products in the US

3rd

largest generic
company in the US

3rd

pharmaceutical
company in the MENA
region

95%

of portfolio
manufactured in-house

32

manufacturing facility

8

R&D center

1980s

- First FDA approval in MENA and expansion in region
- Landed in Portugal

1990s

- West-Ward acquisition in US
- Acquisitions in KSA & Tunisia

2000s

- Acquisitions in Italy, Germany, Egypt, Jordan
- LSE listing

2010s

- Three more acquisitions in US
- Acquisitions in Morocco & Egypt

2020s


- Teligent acquisition in Canada
- Custopharm Acquisition in US

A long and successful history of growth

Doubling revenues every four years

Greenfield projects

Major acquisitions




Source: Company information

Group revenue (\$m)

MENA Pharma Market Insight

(June 2019)



“The key to Hikma's successes thus far has been a willingness to take calculated risks.”

*Melanie Stern; In Rude Health
Families in Business No.24 Jan/Feb 2006*



Export Sales
Vs.
International Business



Iran Pharma Industry

How prepared we are?

